Virtual Library
Start Your Search
J. Díaz-Rico
Author of
-
+
P2.07 - Immunology and Immunotherapy (ID 708)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.07-061 - Nivolumab for Patients with Non-Small Cell Lung Carcinoma in Patients with Progression to One or More Lines of Chemotherapy in Mexican Population (ID 10092)
09:30 - 09:30 | Author(s): J. Díaz-Rico
- Abstract
Background:
: Nivolumab is a PD-1 inhibitor that has been approved as a treatment in adenocarcinoma and squamous cell lung cancer. This study examines the experience with nivolumab as a compassionate use in Mexican patients.
Method:
Descriptive, observational, retrospective and unicentric study that analyzed 38 patients diagnosed with stage III and IV lung cancer who progressed to one or more line of chemotherapy and received nivolumab from April 2016 to March 2017 at the National Institute of Respiratory Diseases. The primary endpoint was overall survival and secondary progression-free survival and response rate measured based on RECIST 1.1.
Result:
The sample was formed by 12 men (35.3%) and 22 women (64.7%), that had an initial ECOG of I in 23.5%, II in 58.5% and III in 17.6% and clinical stages was III 2.9% and IV 97.1%. They were smokers in 52.8% of the patients, with an average of 9.1 packs/year and 47.1% had exposure to smoke from wood, with an average of 62.1 hours/year. The 88.2% had adenocarcinoma, 5.9% squamous, from which 54.4% received nivolumab in second line and 45.6% in third line or more. The median progression-free survival was 8.1 months. The average overall survival, has not been able to achieve since 12 moths of treatment, the 51.4% of patients still alive. The response to the treatment by RECIST 1.1 was 38.2% for partial response (13 patients), stable disease in 41.2% (14 patients) and complete response 20.6% (7 patients).
Conclusion:
The use of nivolumab in patients with non-small cell lung carcinoma in advanced clinical stages (III and IV) progressing to a first line or more of chemotherapy demonstrated a better progression-free survival and overall survival in Mexican patients.
